211 related articles for article (PubMed ID: 27323830)
1. Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.
Aguilera O; Muñoz-Sagastibelza M; Torrejón B; Borrero-Palacios A; Del Puerto-Nevado L; Martínez-Useros J; Rodriguez-Remirez M; Zazo S; García E; Fraga M; Rojo F; García-Foncillas J
Oncotarget; 2016 Jul; 7(30):47954-47965. PubMed ID: 27323830
[TBL] [Abstract][Full Text] [Related]
2. Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic
Cenigaonandia-Campillo A; Serna-Blasco R; Gómez-Ocabo L; Solanes-Casado S; Baños-Herraiz N; Puerto-Nevado LD; Cañas JA; Aceñero MJ; García-Foncillas J; Aguilera Ó
Theranostics; 2021; 11(8):3595-3606. PubMed ID: 33664850
[No Abstract] [Full Text] [Related]
3. L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.
Jung SA; Lee DH; Moon JH; Hong SW; Shin JS; Hwang IY; Shin YJ; Kim JH; Gong EY; Kim SM; Lee EY; Lee S; Kim JE; Kim KP; Hong YS; Lee JS; Jin DH; Kim T; Lee WJ
Free Radic Biol Med; 2016 Jun; 95():200-8. PubMed ID: 27012422
[TBL] [Abstract][Full Text] [Related]
4. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.
Yun J; Mullarky E; Lu C; Bosch KN; Kavalier A; Rivera K; Roper J; Chio II; Giannopoulou EG; Rago C; Muley A; Asara JM; Paik J; Elemento O; Chen Z; Pappin DJ; Dow LE; Papadopoulos N; Gross SS; Cantley LC
Science; 2015 Dec; 350(6266):1391-6. PubMed ID: 26541605
[TBL] [Abstract][Full Text] [Related]
5. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
Wang G; Huang Y; Wu Z; Zhao C; Cong H; Ju S; Wang X
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30674639
[TBL] [Abstract][Full Text] [Related]
6. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
7. A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics.
Wu X; Park M; Sarbassova DA; Ying H; Lee MG; Bhattacharya R; Ellis L; Peterson CB; Hung MC; Lin HK; Bersimbaev RI; Song MS; Sarbassov DD
Int J Cancer; 2020 May; 146(10):2822-2828. PubMed ID: 31472018
[TBL] [Abstract][Full Text] [Related]
8. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
[TBL] [Abstract][Full Text] [Related]
9. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
[TBL] [Abstract][Full Text] [Related]
10. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production.
Iskandar K; Rezlan M; Yadav SK; Foo CH; Sethi G; Qiang Y; Bellot GL; Pervaiz S
Antioxid Redox Signal; 2016 May; 24(14):781-94. PubMed ID: 26714745
[TBL] [Abstract][Full Text] [Related]
12. Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.
Burska AN; Ilyassova B; Dildabek A; Khamijan M; Begimbetova D; Molnár F; Sarbassov DD
Cells; 2022 Nov; 11(21):. PubMed ID: 36359850
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Approach of KRAS Mutant Tumours by the Combination of Pharmacologic Ascorbate and Chloroquine.
Kapuy O; Makk-Merczel K; Szarka A
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33925206
[TBL] [Abstract][Full Text] [Related]
14. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
15. Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications.
El Halabi I; Bejjany R; Nasr R; Mukherji D; Temraz S; Nassar FJ; El Darsa H; Shamseddine A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30217071
[TBL] [Abstract][Full Text] [Related]
16. Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.
Park HJ; Park JB; Lee SJ; Song M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800074
[TBL] [Abstract][Full Text] [Related]
17. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
[TBL] [Abstract][Full Text] [Related]
18. Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis.
Liu M; Wang D; Luo Y; Hu L; Bi Y; Ji J; Huang H; Wang G; Zhu L; Ma J; Kim E; Luo CK; Abbruzzese JL; Li X; Yang VW; Li Z; Lu W
Cell Death Dis; 2021 Feb; 12(2):189. PubMed ID: 33594044
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
Sun C; Hobor S; Bertotti A; Zecchin D; Huang S; Galimi F; Cottino F; Prahallad A; Grernrum W; Tzani A; Schlicker A; Wessels LF; Smit EF; Thunnissen E; Halonen P; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Trusolino L; Bernards R
Cell Rep; 2014 Apr; 7(1):86-93. PubMed ID: 24685132
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
